Novonesis AS

Director's Dealing • Nov 4, 2025

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen matching shares program and the legacy Chr. Hansen 2023 restricted stock units (RSU) program.

1. Details ofthe person discharging managerial responsibilities/person closely associated a) Name Henrik Jørck Nielsen 2. Reason for the notification a) Position/status Executive Vice President, Human Health Biosolutions & Strategy ) Initial notification/Amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Novozymes A/S, part of Novonesis Group b) LEI 529900T6WNZXD2R3JW38 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description ofthe financial instrument, type of instrument Identification code B-shares DK0060336014 b) Nature of the transaction Shares received as part of legacy Chr. Hansen incentive programs c) Price(s) and volume(s) Volume Price (DKK) 9,565 shares 387.40 d) Aggregated information - Aggregated volume - Price 9,565 shares 3,705,481.00 DKK e) Date of the transaction November 3, 2025 f) Place of the transaction Outside a trading venue

November 4, 2025 Company announcement No. 45

Contact information

Tobias Bjorklund +45 3077 8682 tobb@novonesis.com

Anders Enevoldsen +45 5350 1453 adev@novonesis.com

Katrine Spedtsberg Poulsen kats@novonesis.com

About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

Novozymes A/S, part of Novonesis Group Krogshoejvej 36 2880 Bagsvaerd Denmark